1. Home
  2. FTCI vs MGNX Comparison

FTCI vs MGNX Comparison

Compare FTCI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FTC Solar Inc.

FTCI

FTC Solar Inc.

HOLD

Current Price

$3.57

Market Cap

122.4M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.58

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTCI
MGNX
Founded
2017
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
122.4M
115.8M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
FTCI
MGNX
Price
$3.57
$3.58
Analyst Decision
Strong Buy
Hold
Analyst Count
5
5
Target Price
$10.80
$3.40
AVG Volume (30 Days)
135.1K
850.4K
Earning Date
04-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$99,687,000.00
$149,500,000.00
Revenue This Year
$65.44
N/A
Revenue Next Year
$45.97
$16.14
P/E Ratio
N/A
N/A
Revenue Growth
110.51
N/A
52 Week Low
$2.49
$1.11
52 Week High
$12.75
$3.50

Technical Indicators

Market Signals
Indicator
FTCI
MGNX
Relative Strength Index (RSI) 29.46 70.49
Support Level N/A $1.48
Resistance Level $5.23 N/A
Average True Range (ATR) 0.36 0.25
MACD 0.11 0.02
Stochastic Oscillator 7.74 74.79

Price Performance

Historical Comparison
FTCI
MGNX

About FTCI FTC Solar Inc.

FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: